PM
Parametrica Management Portfolio holdings
AUM
$53.8M
This Quarter Return
+11.28%
1 Year Return
+45.44%
3 Year Return
+302.58%
5 Year Return
+406.02%
10 Year Return
–
AUM
$52.9M
AUM Growth
+$52.9M
(-42%)
Cap. Flow
-$41.9M
Cap. Flow
% of AUM
-79.22%
Top 10 Holdings %
Top 10 Hldgs %
36.41%
Holding
174
New
52
Increased
8
Reduced
27
Closed
87
Top Buys
| 1 |
Norwegian Cruise Line
NCLH
|
$1.98M |
| 2 |
Netflix
NFLX
|
$1.45M |
| 3 |
NVIDIA
NVDA
|
$1.23M |
| 4 |
Pfizer
PFE
|
$1.1M |
| 5 |
Capital One
COF
|
$719K |
Top Sells
| 1 |
Invesco QQQ Trust
QQQ
|
$4.61M |
| 2 |
Alibaba
BABA
|
$4.55M |
| 3 |
United Airlines
UAL
|
$3.96M |
| 4 |
Bilibili
BILI
|
$3.92M |
| 5 |
JD.com
JD
|
$2.86M |
Sector Composition
| 1 | Healthcare | 22.43% |
| 2 | Consumer Discretionary | 19.3% |
| 3 | Industrials | 15.1% |
| 4 | Technology | 15.1% |
| 5 | Communication Services | 13.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
AutoZone
AZO
$70.2B
| $319K | 0.6% |
+270
| New | +$319K |
|
52
Philip Morris
PM
$260B
| $309K | 0.58% |
+4,120
| New | +$309K |
|
53
Teladoc Health
TDOC
$1.37B
| $304K | 0.57% |
+1,385
| New | +$304K |
|
54
Genuine Parts
GPC
$19.4B
| $302K | 0.57% |
+3,170
| New | +$302K |
|
55
Curtiss-Wright
CW
$18B
| $290K | 0.55% |
+3,107
| New | +$290K |
|
56
Citigroup
C
$178B
| $288K | 0.54% |
6,690
+1,786
| +36% | +$76.9K |
|
57
Masco
MAS
$15.4B
| $286K | 0.54% |
+5,176
| New | +$286K |
|
58
Apple
AAPL
$3.45T
| $282K | 0.53% |
2,436
-2,309
| -49% | -$267K |
|
|
HZNP
59
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $281K | 0.53% |
+3,620
| New | +$281K |
|
|
RETA
60
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $280K | 0.53% |
2,875
+1,051
| +58% | +$102K |
|
61
Cintas
CTAS
$84.6B
| $272K | 0.51% |
+816
| New | +$272K |
|
62
Freeport-McMoran
FCX
$63.7B
| $269K | 0.51% |
+17,198
| New | +$269K |
|
63
Okta
OKTA
$16.4B
| $264K | 0.5% |
1,232
-594
| -33% | -$127K |
|
64
Zoetis
ZTS
$69.3B
| $250K | 0.47% |
1,510
-1,407
| -48% | -$233K |
|
65
Johnson Controls International
JCI
$69.9B
| $248K | 0.47% |
+6,084
| New | +$248K |
|
66
ResMed
RMD
$40.2B
| $242K | 0.46% |
+1,411
| New | +$242K |
|
67
AbbVie
ABBV
$372B
| $241K | 0.46% |
+2,758
| New | +$241K |
|
68
Trimble
TRMB
$19.2B
| $237K | 0.45% |
+4,864
| New | +$237K |
|
69
Halliburton
HAL
$19.4B
| $233K | 0.44% |
+19,317
| New | +$233K |
|
70
Nektar Therapeutics
NKTR
$568M
| $226K | 0.43% |
+13,658
| New | +$226K |
|
71
Bio-Rad Laboratories Class A
BIO
$8.06B
| $224K | 0.42% |
+435
| New | +$224K |
|
72
Ford
F
$46.8B
| $224K | 0.42% |
+33,646
| New | +$224K |
|
73
CBRE Group
CBRE
$48.2B
| $223K | 0.42% |
4,738
-13,085
| -73% | -$616K |
|
74
CVS Health
CVS
$92.8B
| $219K | 0.41% |
+3,757
| New | +$219K |
|
75
Lam Research
LRCX
$127B
| $215K | 0.41% |
+650
| New | +$215K |
|